Page 14 - Bharat Biotech

Russia's Sputnik V vaccine to be available in India from next week: Govt

India expecting 156 million doses of the vaccine from August to September

Delhi govt urges Serum Institute to 'come to rescue' and provide Covishield

To this, the SII said they are doing their best to meet countrywide vaccine requirements.

Bharat Biotech's Covaxin approved for phase 2/3 trials on children

India's apex drug regulator has granted permission for conducting the phase II/III clinical trial of Bharat Biotech's Covaxin Covid-19 vaccine in the age group of 2 to 18 years

Avoid unrealistic Covid-19 vaccine expectations: Harsh Vardhan to states

The health minister was holding a meeting with eight states that have been showing a higher number of daily cases, positivity rate and mortality

Bharat Biotech trial nod a turning point for paediatric Covid-19 vaccine

Bharat Biotech has already conducted trials on children 12 years and above

Maharashtra, Karnataka suspend Covid-19 vaccination for 18-44 age group

Delhi's Deputy Chief Minister Manish Sisodia accused the Centre of blocking supplies to the state.

Will raise monthly production of vaccines to 100 mn doses by August: Serum

Amid multiple states reporting a shortage of COVID-19 vaccine, Serum Institute and Bharat Biotech have submitted to the Centre their production plan for the next four months, informing they can ramp it up to 10 crore and 7.8 crore doses respectively by August, official sources said on Wednesday The sources said the Union Health Ministry and the office of Drugs Controller General of India had sought from both the firms their production plan for June, July, August and September. The Hyderabad-based Bharat Biotech's indigenously developed Covaxin and Oxford-AstraZeneca's Covishield, being manufactured by the Pune-based Serum Institute of India, are currently being used in India's inoculation drive against coronavirus. Dr V Krishna Mohan, the Whole-time Director of Bharat Biotech, is learnt to have conveyed to the government that the production of Covaxin would be raised to 3.32 crore in July, and to 7.82 crore in August which will be maintained in September too. Similarly, Prakash Kum

'Disheartening to see some states complain about our Covaxin intentions'

It is quite disheartening to listen to some states complaining about Bharat Biotech's intentions regarding supply of COVID vaccine Covaxin, a top company official said on Wednesday. In a tweet, Bharat Biotech Joint Managing Director Suchitra Ella said the company has already dispatched Covaxin lots to 18 states on May 10. "18 states have been covered though in smaller shipments. Quite disheartening to the teams to hear some states complaining about our intentions. 50 of our employees are off work due to covid, yet we continue to work under pandemic lockdowns 24x7 for U," she said in a tweet. The Hyderabad-based firm is supplying Covaxin to 18 states, including Andhra Pradesh, Haryana, Odisha, Assam, Jammu & Kashmir, Tamil Nadu, Bihar, Jharkhand and Delhi. Other states are Chhattisgarh, Karnataka, Telangana, Tripura, Madhya Pradesh, Uttar Pradesh, Gujarat, Maharashtra and West Bengal. Earlier in the day, Delhi Deputy Chief Minister Manish Sisodia said Bharat Biotech has informed ...

Experts recommend Covaxin for phase 2/3 trials on those aged 2-18 year

Bharat Biotech's Covid-19 vaccine Covaxin was on Tuesday recommended by an expert panel for phase II/III clinical trial on those aged between two to 18 years, official sources said

Direct supply of Covaxin to 18 states since May 1: Bharat Biotech

Bharat Biotech on Tuesday said it will continue the steady supply of its COVID-19 vaccine Covaxin, adding the jab has been directly supplied to 18 states since May 1. The states include Andhra Pradesh, Delhi, Bihar, Gujarat, Haryana, Uttar Pradesh and West Bengal, the Hyderabad-based firm added. "COVAXIN has been directly supplied to 18 states since May 1st. Unflinching in our efforts, we will continue the steady supply of our #vaccine," Bharat Biotech said in a tweet. The company is supplying its vaccine to Andhra Pradesh, Assam, Bihar, Chhattisgarh, Delhi, Gujarat, Haryana, Jammu & Kashmir, Jharkhand, Karnataka, Madhya Pradesh, Maharashtra, Odisha, Tamil Nadu, Tripura, Telangana, Uttar Pradesh and West Bengal. Bharat Biotech has commenced direct supply of Covaxin with effect from May 1 to several states based on the allocations received by the central government, the company's Joint Managing Director Suchitra Ella had earlier said. On April 29, Bharat Biotech had announced a cut

Bharat Biotech commences direct supply of 'Covaxin' to 14 states

The company is now getting requests from other state governments as well, and will be processing them for distribution based on availability of the vaccine

Bharat Biotech commences direct supply of Covaxin to 14 states

Bharat Biotech has commenced direct supply of its COVID-19 vaccine 'Covaxin' to 14 states, including Delhi and Maharashtra, with effect from May 1, according to the company's Joint Managing Director Suchitra Ella. The Hyderabad-based firm has started supplying its COVID-19 treatment vaccine to the states based on the allocations received by the central government. "Bharat Biotech confirms direct supplies of COVAXIN to the following state govt's since 1/5/21, based on the allocations received by GoI. Requests have been received from other states, & will be processed for distribution based on availability of stocks 24x7," Ella tweeted. The company is supplying vaccines to Andhra Pradesh, Assam, Chhattisgarh, Gujarat, Jammu & Kashmir, Jharkhand, Madhya Pradesh, Odisha, Tamil Nadu, Telangana, Uttar Pradesh and West Bengal. On April 29, Bharat Biotech announced a cut in the price of 'Covaxin' for states to Rs 400 per dose from the earlier Rs 600 per dose. This followed widespread ..

After just Rs 18,000 cr profits in a decade, Serum, Bharat Biotech may earn big with Covid

For both companies, the pandemic presents a once-in-a-lifetime opportunity to earn hundreds of crores of rupees that could be ploughed back to fund further research and capacity expansion

Covid-19 2nd wave: Reports of no fresh vaccine order incorrect, says govt

Business Standard had reported in Monday's edition of the newspaper that the Centre had not yet placed fresh orders with the vaccine manufacturers. We stand corrected.

Bharat Biotech follows SII, reduces Covaxin price to Rs 400 for states

Earlier, the Bharat Biotech vaccine was priced at Rs 600 a dose

Serum cuts Covishield price by 25% for states, no change for pvt hospitals

Bharat Biotech is yet to announce any change in prices of Covaxin

India's Covaxin vaccine 'very important antidote' against Covid: Dr Fauci

Covaxin works by teaching the immune system to make antibodies against the SARS-CoV-2 coronavirus, NYT reports separately.

In a nation of inequalities, India's vaccine strategy is bad economics

Free, universal access to inoculation could prepare India better for a third Covid-19 resurgence.

After states' objection, Centre asks vaccine manufacturers to lower prices

SII and Bharat Biotech had announced prices for state government procurement and for institutional sale to private hospitals

State govts begin vaccine price negotiations, eye Rs 150 per dose

States would have to fund procurement from their own budgets and bridge funding from the Centre is unlikely